Tobramycin
| Evidence Level: L5 | Predicted Indications: 67 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Tobramycin |
| DrugBank ID | DB00684 |
| Brand Names (EU) | Tobi Podhaler, Vantobra (previously Tobramycin PARI) |
| Evidence Level | L5 |
| Predicted Indications | 67 |
| Top Prediction Score | 99.99% |
Approved Indication (EMA)
Vantobra is indicated for the management of chronic pulmonary infection due to Pseudomonas aeruginosa in patients aged 6 years and older with cystic fibrosis (CF). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | punctate epithelial keratoconjunctivitis | 99.99% | DL |
| 2 | exposure keratitis | 99.93% | DL |
| 3 | non-human animal disease | 99.83% | DL |
| 4 | otitis externa | 99.81% | DL |
| 5 | postinfectious vasculitis | 99.80% | DL |
| 6 | post-bacterial disorder | 99.79% | DL |
| 7 | post-infectious syndrome | 99.79% | DL |
| 8 | infective urethral stricture | 99.78% | DL |
| 9 | Chagas cardiomyopathy | 99.78% | DL |
| 10 | infection-related hemolytic uremic syndrome | 99.78% | DL |
| 11 | neurotrophic keratopathy | 99.77% | DL |
| 12 | acute contagious conjunctivitis | 99.66% | DL |
| 13 | superior limbic keratoconjunctivitis | 99.48% | DL |
| 14 | conjunctivitis | 99.43% | DL |
| 15 | epidemic keratoconjunctivitis | 99.38% | DL |
| 16 | eye infectious disease | 99.38% | DL |
| 17 | globe disease | 99.35% | DL |
| 18 | papillary conjunctivitis | 99.33% | DL |
| 19 | bronchitis | 99.14% | DL |
| 20 | blepharoconjunctivitis | 99.12% | DL |
Showing top 20 of 67 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.